Michael B Cossoy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Michael B Cossoy has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Amit Kamboj
Department of Pharmacology and Therapeutics, University of Manitoba and Division of Neurodegenerative Disorders, St Boniface Hospital Research, Winnipeg, Canada
1 shared publication - Brian A Dolhun
Department of Pharmacology and Therapeutics, University of Manitoba and Division of Neurodegenerative Disorders, St Boniface Hospital Research, Winnipeg, Canada
1 shared publication - Christopher M. Anderson
Department of Pharmacology and Therapeutics, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada
1 shared publication - Gilbert de Murcia
Department ‘Intégrité du Génome’ de l’UMR 7175, École Supérieure de Biotechnologie de Strasbourg, Illkirch Cedex, France
1 shared publication - Jillian L. Stobart
Centre on Aging, University of Manitoba, Winnipeg, Manitoba, Canada
1 shared publication - Ping Lu
Department of Pharmacology and Therapeutics, University of Manitoba and Division of Neurodegenerative Disorders, St Boniface Hospital Research, Winnipeg, Canada
1 shared publication
Latest Publications
- Open Access
- 22 April 2013
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 10 (1) , 49
Poly(ADP-ribose) polymerase 2 contributes to neuroinflammation and neurological dysfunction in mouse experimental autoimmune encephalomyelitis
Background: Experimental autoimmune encephalomyelitis (EAE) is an animal model of multiple sclerosis characterized by entry of activated T cells and antigen presenting cells into the central nervous system and subsequent autoimmune destruction of nerve myelin. Previous studies revealed that non-selective inhibition of poly(ADP-ribose) polymerases (PARPs) 1 and 2 protect against neuroinflammation and motor dysfunction associated with EAE, but the role of the PARP-2 isoform has not yet been investigated selectively. Results: EAE was induced in mice lacking PARP-2, and neurological EAE signs, blood-spine barrier (BSB) permeability, demyelination and inflammatory infiltration were monitored for 35 days after immunization. Mice lacking PARP-2 exhibited significantly reduced overall disease burden and peak neurological dysfunction. PARP-2 deletion also significantly delayed EAE onset and reduced BSB permeability, demyelination and central nervous system (CNS) markers of proinflammatory Th1 and Th17 T helper lymphocytes. Conclusions: This study represents the first description of a significant role for PARP-2 in neuroinflammation and neurological dysfunction in EAE.
- 22 April 2013
- Published by Springer Nature in Journal of Neuroinflammation
- Vol. 10 (1) , 49
Open AccessPoly(ADP-ribose) polymerase 2 contributes to neuroinflammation and neurological dysfunction in mouse experimental autoimmune encephalomyelitis
Background: Experimental autoimmune encephalomyelitis (EAE) is an animal model of multiple sclerosis characterized by entry of activated T cells and antigen presenting cells into the central nervous system and subsequent autoimmune destruction of nerve myelin. Previous studies revealed that non-selective inhibition of poly(ADP-ribose) polymerases (PARPs) 1 and 2 protect against neuroinflammation and motor dysfunction associated with EAE, but the role of the PARP-2 isoform has not yet been investigated selectively. Results: EAE was induced in mice lacking PARP-2, and neurological EAE signs, blood-spine barrier (BSB) permeability, demyelination and inflammatory infiltration were monitored for 35 days after immunization. Mice lacking PARP-2 exhibited significantly reduced overall disease burden and peak neurological dysfunction. PARP-2 deletion also significantly delayed EAE onset and reduced BSB permeability, demyelination and central nervous system (CNS) markers of proinflammatory Th1 and Th17 T helper lymphocytes. Conclusions: This study represents the first description of a significant role for PARP-2 in neuroinflammation and neurological dysfunction in EAE.